Studies on the anticholinesterase and twitch potentiation activities of galanthamine.

doi:10.1254/JJP.12.111

Paper

Studies on the anticholinesterase and twitch potentiation activities of galanthamine.

Published Dec 1, 1962 · M. Ueda, S. Matsumura, S. Kimoto

Japanese journal of pharmacology

UNKNOWN SJR score

7

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Following the isolation of galanthamine by Proskurina (1) and Uyeo (2), Mashkovskiy (3, 4) reported that cholinesterase activity was depressed and sensitivity of striated muscles to acetylcholine was increased by the administration of galanthamine. Sedova (5) also recognized that galanthamine administration caused myosis, salivation, and the activation of smooth muscle movement in experimental animals. Hence the application of galanthamine for the therapy of myopathy, myasthenia gravis, radiculitis, and polyneuritis was suggested. Anticholinesterase activities of galanthamine were further examined by Irwin et at. (6, 7). After examining both the anticholinesterase activity and twitch potentiation of several galanthamine derivatives, they concluded that galanthamine methiodide was the most active. It seems, however, that something still re_naines to be clarified in the correlation between the twitch potentiation and anticholinesterase activity of galanthamine derivatives. The present experiments were chiefly carried out to clarify this point. Subsequently, comparisons of galanthamine were made with other anticholinesterases i.e. neostigmine, physostigmine, and DFP, in regards to muscle twitch potentiation, anticholinesterase activity, and in the activation of the motor nerve terminals.

Study Snapshot

Galanthamine has potential therapeutic applications in myopathies, myasthenia gravis, radiculitis, and polyneuritis due to its anticholinesterase activity and twitch potentiation properties.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Studies on the anticholinesterase and twitch potentiation activities of galanthamine.

Sign up to use Study Snapshot

References

Citations

Kinetic and structural studies on the inhibition of acetylcholinesterase and butyrylcholinesterase by a series of multitarget-directed galantamine-peptide derivatives.

Multitarget anti-Alzheimer compounds designed by combining galantamine and BACE-1 inhibitory peptide fragments show promising potential for designing more effective Alzheimer's treatments.

Kinetic Modeling of Time-Dependent Enzyme Inhibition by Pre-Steady-State Analysis of Progress Curves: The Case Study of the Anti-Alzheimer’s Drug Galantamine

The conventional steady-state model for enzyme inhibition underestimates the potency of Alzheimer's drug galantamine by a factor of 100, due to its time-dependent nature.

The role of high-fat diet in an APP/PS1 model of familial Alzheimer disease = Efecto de una dieta rica en grasas en ratones APP/PS1, modelo familiar de la enfermedad de Alzheimer

A high-fat diet can significantly worsen Alzheimer's disease symptoms in mice, with metabolic syndrome, diabetes, and related comorbidities potentially contributing to the disease's progression.

Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice

Galanthamine, a long-acting acetylcholinesterase inhibitor, may effectively treat central cholinergic deficits in Alzheimer's disease by improving cognitive deficits in mice with nucleus basalis magnocellularis lesions.

Preclinical and Clinical Studies with Galanthamine

Galanthamine, a plant-derived alkaloid, shows weak analgesic effects in animals and can penetrate the blood-brain barrier.